3 results about "Soluble Tablet" patented technology

This application discloses nalmefene base, its preparation method, and its application, belonging to the field of pharmaceutical technology. The preparation method of nalmefene includes the following steps: mixing nalmefene hydrochloride with water to form an aqueous solution of nalmefene hydrochloride; reacting the aqueous solution of nalmefene hydrochloride with an aqueous solution of an alkaline component to form nalmefene base; the pH of the nalmefene hydrochloride is 4.0-6.5; the alkaline component includes at least one selected from sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, sodium acetate, ammonia, and sodium dihydrogen phosphate. This application uses nalmefene hydrochloride with a pH of 4.0-6.0 to undergo a desalting reaction with an aqueous solution of a strong base-weak acid salt or a weak base, crystallizing out nalmefene base. This effectively controls the particle size and shape of nalmefene base, obtaining small-particle-size, low-content, stable, and poorly soluble tablet-shaped nalmefene base without pulverization. It is less prone to burst release, meeting the requirements for sustained-release formulations, and the reaction is mild, green, and economical.

Described herein are formulations of a peptide derived from Chaperonin 60.1 suitable for sublingual administration. A dissolvable tablet pharmaceutical formulation is designed for sublingual administration of a Chaperonin 60.1-derived peptide. This dissolvable tablet formulation includes a matrix-forming agent, a surfactant, a pH modifier, and a solvent. It may also contain sweeteners, flavor enhancers, or flavoring agents. In addition, a liquid pharmaceutical formulation is designed for sublingual administration of a Chaperonin 60.1-derived peptide. This liquid pharmaceutical formulation includes the peptide, bovine serum albumin, and phosphate-buffered saline. The sublingual formulations achieve rapid systemic delivery comparable to IV administration. These formulations are intended for treating inflammatory conditions through sublingual administration. The formulations can be used for various inflammatory conditions and are adaptable for different administration frequencies and subject types.

The application belongs to the technical field of medicine, and specifically provides an entero-soluble ibrexin tablet with high bioavailability and a preparation method thereof. The entero-soluble tablet comprises a tablet core and an enteric coating, wherein the tablet core comprises an ibrexin coating compound, microcrystalline cellulose and magnesium stearate, and the ibrexin coating compound comprises ibrexin or a pharmaceutically acceptable salt thereof, an acid regulator, povidone and cross-linked sodium carboxymethyl cellulose. The ibrexin entero-soluble tablet of the application can make the drug reach the end of the small intestine or the colon for release, thereby avoiding the metabolism of cytochrome P450 (CYP) 3A, and at the same time, the acid regulator can locally provide an acidic environment for the active ingredient, so that the ibrexin is rapidly dissolved and released, and the side effects such as vomiting in the gastrointestinal tract are reduced.